Australia markets closed

TFF Pharmaceuticals, Inc. (TFFP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.9499-0.0191 (-1.97%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.9690
Open0.9066
Bid0.9100 x 1000
Ask0.9699 x 1100
Day's range0.9066 - 0.9800
52-week range0.8100 - 7.7000
Volume97,928
Avg. volume218,895
Market cap34.38M
Beta (5Y monthly)1.26
PE ratio (TTM)N/A
EPS (TTM)-1.2510
Earnings date22 Mar 2023 - 27 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.00
  • GlobeNewswire

    TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer

    FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer. Dr. Mikhak will be responsible for the clinical development of the Company’s pipeline candidates, including the Inhaled Voriconazole Powder and Inhaled

  • GlobeNewswire

    TFF Pharmaceuticals Announces Leadership Transition

    Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer FORT WORTH, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that Glenn Mattes will ste

  • GlobeNewswire

    TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering

    Underwriters Exercise Their Option in FullFORT WORTH, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced underwritten offering of 10,675,001 shares of its common stock and warrants to purchase up to 5,337,501 shares of common stock. T